摘要
目的:观察利妥昔单抗联合环磷酰胺、长春新碱、表柔比星及泼尼松(CHOP方案)治疗弥漫性大B细胞淋巴瘤(DLBCL)的疗效和不良反应。方法:采用利妥昔单抗+CHOP方案对4例DLBCL患者进行联合化疗,21d为1个周期。结果:随访14个月,4例患者均处于完全缓解中,无明显不良反应。结论:利妥昔单抗联合CHOP方案治疗DLBCL,疗效好,不良反应小。
Objective： To observe the effect and side effect of combination treatment of rituximab, cyclophosphamide, vincristine, epirubicin and prednisone （CHOP） on diffuse large B-cell lymphoma （DLBCL）.Methods： Employed combined chemical therapy with rituximab and CHOP to 4 DLBCL patients for 21 d per course. Results： Follow-up of 14 months showed 4 cases were totally relieved without any side effect. Conclusion： Combination treatment of rituximab and CHOP is effective and of little side effect.
出处
《海南医学院学报》
CAS
2009年第11期1398-1399,1402,共3页
Journal of Hainan Medical University
基金
海南医学院科研基金资助学报项目(0020090231)~~
